Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
In the interim, Deepak Khanna will lead Human Health International.
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Subscribe To Our Newsletter & Stay Updated
